Agila, Pfenex sign biosimilar joint venture deal

04/17/2013 | Genetic Engineering & Biotechnology News

Pfenex and Agila Biotech agreed to develop, manufacture and market six biosimilars as part of a joint venture. Pfenex will combine its strain engineering and process development know-how with Agila's biologics production and clinical development expertise. The venture's lead product will be interferon beta-1b, a biosimilar version of multiple sclerosis treatment Betaseron.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN